Micafungine Teva

Micafungin, the active ingredient in Micafungine Teva, is an echinocandin presented as a injection for intravenous use. It treats invasive fungal infections such as candidiasis in immunocompromised patients, including prophylaxis for stem‑cell transplant recipients. GNH USA supplies Micafungine Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Micafungine Teva is an echinocandin antifungal that targets Candida species in serious infections. - Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: resolves mucosal lesions and symptoms in immunocompromised patients. - Candida peritonitis and intra‑abdominal infections: aids in clearing infection after abdominal surgery. - Prophylaxis of Candida infections in hematopoietic stem cell transplantation: prevents invasive candidiasis in high‑risk transplant recipients.

Micafungine Teva may cause a range of adverse reactions, most of which are manageable.

Common Side Effects: - Fever: transient temperature elevation during infusion. - Nausea: mild gastrointestinal upset. - Headache: occasional mild to moderate pain. - Infusion‑related reactions: erythema, flushing, or mild hypotension. - Elevated liver enzymes: transient increase in ALT/AST. - Rash: mild skin irritation or pruritus.

Serious or Rare Side Effects: - Hepatic failure: severe liver injury requiring monitoring. - Anaphylaxis: life‑threatening allergic reaction. - Stevens‑Johnson syndrome: severe skin and mucosal involvement. - Renal impairment: acute kidney injury in susceptible patients. - Neutropenia: marked reduction in white blood cells. - Severe hypotension: marked drop in blood pressure during infusion.

Before initiating therapy, clinicians should consider several safety measures. - Renal function monitoring: assess creatinine clearance in patients with kidney disease. - Hepatic function monitoring: check baseline and periodic liver enzymes. - Concomitant hepatotoxic drugs: avoid or adjust dosing when used with other liver‑affecting agents. - Known hypersensitivity: do not administer to patients with documented allergy to micafungin or other echinocandins. - Dose adjustment in severe hepatic impairment: consider reduced exposure and monitor closely. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungine Teva can interact with several medications; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Co‑administration with other echinocandins: may increase toxicity without added benefit. - Strong CYP3A4 inducers (e.g., rifampin): can markedly reduce micafungin exposure. - Cyclosporine: concurrent use may raise micafungin plasma levels.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may increase risk of hepatotoxicity. - Immunosuppressants (e.g., tacrolimus): monitor drug levels and liver function. - Nephrotoxic agents (e.g., aminoglycosides): watch for additive renal impairment.